Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Journal of Neuroendocrinology|February 4, 2026
Determinants of incidence trends in pancreatic neuroendocrine neoplasmsGiuseppe Lamberti, Elisa Andrini, Adriana Di Odoardo, et al.Journal of Clinical Medicine|August 28, 2025
Updates on Pulmonary Neuroendocrine Carcinoids: Progress and PerspectivesAnna Scognamiglio, Arianna Zappi, Elisa Andrini, et al.Expert Opinion on Drug Discovery|July 11, 2025
From bench to bedside: the development journey of fruquintinib as a colorectal cancer therapyMaría San-Román-Gil, Lucrezia Zumstein, Arianna Zappi, et al.JCO Precision Oncology|June 1, 2023
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-AnalysisMirta Mosca, Nicole Conci, Alessandro Di Federico, et al.Journal of Clinical Medicine|January 21, 2023
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative ReviewArianna Zappi, Irene Persano, Linda Galvani, et al.Endocrine|January 24, 2025
Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoidsLinda Galvani, Arianna Zappi, Sara Pusceddu, et al.Cancers|December 11, 2022
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with ImmunotherapyAndrea De Giglio, Elisa Tassinari, Arianna Zappi, et al.Cancer Treatment Reviews|July 6, 2024
Challenges and future perspectives for the use of temozolomide in the treatment of SCLCElisa Andrini, Gianluca Ricco, Arianna Zappi, et al.Pathology, Research and Practice|August 20, 2024
TP53 mutations and survival in patients with histologically defined Glioblastoma, IDH-wildtypeVincenzo Di Nunno, Lidia Gatto, Alicia Tosoni, et al.Pageof 1